News Coronavirus EMA: compassionate use of remdesivir for patients not on mechanical ventilation

EMA: compassionate use of remdesivir for patients not on mechanical ventilation

EMA’s human medicines committee (CHMP) has recommended expanding the compassionate use of the investigational medicine remdesivir so that more patients with severe COVID‑19 can be treated.

In addition to patients undergoing invasive mechanical ventilation, the compassionate use recommendations now cover the treatment of hospitalised patients requiring supplemental oxygen, non-invasive ventilation, high-flow oxygen devices or ECMO (extracorporeal membrane oxygenation).

The updated recommendations are based on preliminary results from the NIAID-ACTT study, which suggest a beneficial effect of remdesivir in the treatment of hospitalised patients with severe COVID-19. EMA is currently evaluating these data in the context of the rolling review of remdesivir.

In addition, a treatment duration of 5 days has been introduced alongside the longer 10-day course, based on preliminary results from another study (GS-US-540-5773) suggesting that for patients not requiring mechanical ventilation or ECMO, the treatment course may be shortened from 10 to 5 days without any loss of efficacy.

Patients who receive a 5-day treatment course but do not show clinical improvement will be eligible to continue receiving remdesivir for an additional 5 days. The option to shorten treatment duration also means that more patients may be able to receive the medicine, which is in very high demand worldwide.

Although remdesivir is not yet authorised for marketing in the European Union, these recommendations for compassionate use will help some patients with severe COVID-19 access the medicine while EMA evaluates data on its benefits and risks. When the evaluation is complete, EMA will make a recommendation on whether or not remdesivir should receive a marketing authorisation.

More about the medicine

Remdesivir is an antiviral medicine which is being investigated for the treatment of COVID-19. Remdesivir is a ‘viral RNA polymerase inhibitor’ (a medicine that interferes with the production of viral genetic material, preventing the virus from multiplying). It has shown broad in vitro activity against different RNA viruses, including SARS-CoV-2 and was originally developed for the treatment of Ebola virus disease.

Remdesivir is being developed by Gilead Sciences Ireland CU and is given by infusion (drip) into a vein.

More about the procedure

National competent authorities can ask EMA for an opinion on how to administer, distribute and use certain medicines for compassionate use under Article 83 of Regulation (EC) No 726/2004.

Compassionate use programmes enable patients to gain access to unauthorised medicines in emergency situations. This complements the possibility to enroll patients in ongoing clinical trials.

Top Stories

Where to get a rapid test Monday March 1st

  Aiming towards the monitoring of the community and workplaces, the  government continues free programmes of rapid antigen testing for employees of businesses that have...

Covid relaxations in occupied north tomorrow, as cafes and restaurants reopen

  Cafeterias, restaurants and on the road food stalls reopen tomorrow in the occupied north, as a number of covid relaxations come into force. The...

No compromises on vaccine safety, EMA chief tells Philenews

  Vigilance, patience, but not concern, is the advice of the European Medicines Association chief Emer Cook, who assured in an interview to Philenews that...

Guterres invitation on Cyprus five party conference reaches Tatar

  The Turkish-Cypriot leader Ersin Tatar today received an official invitation from UN Secretary General Antonio Guterres to attend a five party informal conference on...

Eleven drivers under substance influence in two weeks

  Eleven drivers have been found positive to drug substances following traffic checks over the  past two weeks, from February 11 to 28. In the latest...

Taste

Squash soup

Ingredients: 1 kg pumpkin, cut into small cubes, approximately 5 cups 2 medium (400g) sweet potatoes, cut into cubes, approximately 2 ½ cups 1 chopped leek, only...

Mezedes

No visit to Cyprus is complete without enjoying the traditional meal of many small dishes known as ‘meze’. This large feast, which has been a...

Prawns with fried cheese, barley shaped pasta

Put the barley shaped pasta into a small pan with salted water, bring to a boil and when tender, drain. Peal the prawns leaving...

Salmon and shrimp sheftalies

Mix all ingredients for tabbouli in a bowl and keep to one side so flavours can combine. Prepare the sheftalies: wash and soak the casing...